ClinicalTrials.gg
CompletedNCT05166837Updated Dec 20, 2023

The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects

A Phase 1 interventional study of STSA-1002 injection and Placebo in Healthy, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Completed at 5 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled, single-ascending dose Phase Ⅰa study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 following intravenous infusion in healthy subjects

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, aged ≥ 18 but ≤ 65, male and female;
  • : 18.0 -25.0 kg/m2, inclusive;
  • Subjects (including their partners) agree to take highly effective measures during the study, and they have no birth plan or sperm donation plan within 5 months after the end of the study;
  • Medical histories, physical examinations, laboratory examinations and study-related examinations and tests of the subjects show normal results or mild abnormalities with no clinical significance before enrollment, and the Investigator judges that they are eligible;
  • Subjects are aware of the risks of the study, and voluntarily participate in the clinical study and sign an form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Past history of tuberculosis, history of contact with active tuberculosis, and positive tuberculin test results;
  • History of cardiovascular, respiratory, kidney, liver, metabolism, endocrine, gastrointestinal, blood, nerve, skin and mental illness, cancer or other major disease that in the judgment of the Investigator might put the subject as risk on this study;
  • There is a clear history of food or drug allergy or the total serum immunoglobulin IgE is higher than the ;
  • Positive screening test results for (HIV-1/HIV-2) antibodies, surface antigen (HBsAg) or antibody (HCVAb);
  • Presence of vital signs values or of (ECG) abnormalities during the screening period, as defined by an Investigator;
  • ANA positive;
  • During the screening period, the white blood cell count and C-reactive protein test results are abnormal and have clinical significance, : male \<120g/L or female \<110g/L;
  • Smoking more than 5 cigarettes per day or equivalent amount of tobacco in the 3 months before screening;
  • Subjects whose daily consumption of alcohol at the time of screening or at any time within the prior 6 months is more than 2 standard drinks, where 1 standard drink = 355 mL or 12 oz (1 can) of regular-strength (5%) beer; 150 mL or 5 oz wine; 45 mL or 1.5 oz liquor/spirits (40%);
  • Subjects who had a history of drug abuse or tested positive for drugs within 1 year before screening;
  • Subjects who have donated either more than approximately 500 mL of blood (exclusive plasma donation) within 3 mooth prior to screening or any plasma within 4 weeks prior to screening;
  • Participate in any drug or vaccine clinical trial as a subject within 3 months before screening or prepare to be vaccinated during the study period to 2 months after the end of the study;
  • Have taken drugs that may affect immune function within 6 months before screening or have received any monoclonal antibody or biological agent treatment within the previous 3 months and have taken prescription/over-the-counter drugs, herbal medicines, vitamins or other supplements within the previous 14 days;
  • Drink more than 5 cups of coffee, tea or cola per day (150ml and above per cup);
  • Women who are pregnant or breastfeeding;
  • People with a history of fainting, bleeding and needles;
  • The investigator believes that there are any subjects who are not suitable to participate in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Cohort 1:2mg/kg

    All participants (fasted) received either 2 mg/kg of STSA-1002 as a single dose or dose-matched placebo.

    Drug: STSA-1002 injection · Drug: Placebo

  • Experimental
    Cohort 2:5mg/kg

    All participants (fasted) received either 5 mg/kg of STSA-1002 as a single dose or dose-matched placebo.

    Drug: STSA-1002 injection · Drug: Placebo

  • Experimental
    Cohort 3:10mg/kg

    All participants (fasted) received either 10 mg/kg of STSA-1002 as a single dose or dose-matched placebo.

    Drug: STSA-1002 injection · Drug: Placebo

  • Experimental
    Cohort 4:20mg/kg

    All participants (fasted) received either 20 mg/kg of STSA-1002 as a single dose or dose-matched placebo.

    Drug: STSA-1002 injection · Drug: Placebo

  • Experimental
    Cohort 5:30mg/kg

    All participants (fasted) received either 30 mg/kg of STSA-1002 as a single dose or dose-matched placebo.

    Drug: STSA-1002 injection · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram Abnormalities, Clinically Significant Vital Signs Abnormalities And Clinically Significant Physical Examination Abnormalities.

    Time frame: 48 days

  2. Maximum plasma concentration (Cmax)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  3. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  4. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  5. Time of maximum concentration (Tmax)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  6. Elimination half-life (t1/2)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  7. Elimination rate constant of plasma drug concentration in terminal phase (λz)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  8. Last measurable concentration (Clast)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  9. Mean residence time (MRT)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  10. Clearance (CL)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

  11. Apparent volume of distribution (Vz)

    To evaluate the pharmacokinetics (PK) characteristics of STSA-1002 in healthy adult subjects

    Time frame: Up to 1152 hours postdose

Secondary outcomes

  1. Change from baseline in concentration of free C5a and anti-drug antibody

    To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 in healthy subjects

    Time frame: Up to 1152 hours postdose

  2. Change from baseline in concentration of CH50, IL-6, IL-8,C4, TNF-α, IFN-γ

    To evaluate the effect of STSA-1002 on CH50, IL-6, IL-8, C4,TNF-α, IFN-γ

    Time frame: Up to 1152 hours postdose

07

Study locations

5 sites
  • The second hospital of Anhui medical university
    Hefei, Anhui 230601, China
  • Peking university People's Hospital
    Beijing, Beijing 102600, China
  • The fifth affiliated hosipital of Guangzhou medical university
    Guangzhou, Guangdong 510799, China
  • Peking university Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • The affiliated hospital of Guizhou medical university
    Guiyang, Guizhou 550004, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Jan 2023, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2021
First posted
Dec 22, 2021
StartActual
Jan 10, 2022
Primary completionActual
Jan 12, 2023
CompletionActual
Jan 12, 2023
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05166837
Responsible party
Sponsor
First posted
Dec 22, 2021
Start date
Jan 10, 2022
Primary completion
Jan 12, 2023
Completion
Jan 12, 2023
Last update
Dec 20, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Greziprubart

Start the discussion